Mesoblast Limited (NASDAQ:MESO) announced on 2025‑10‑07 that gross revenue from Ryoncil (remestemcel‑L‑rknd) sales for the quarter ended September 30, 2025 was $21.9 million, up 66 % from the $13.2 million reported for the prior quarter. The gross‑to‑net adjustment remained consistent with the first‑quarter launch period, indicating stable pricing and reimbursement dynamics.
Ryoncil is the first mesenchymal stromal cell product approved by the U.S. Food and Drug Administration for any indication and the only therapy approved for children under 12 with steroid‑refractory acute graft‑versus‑host disease. The company noted that the permanent J‑Code assigned by Centers for Medicare & Medicaid Services became active on October 1, 2025, which is expected to further enhance payer coverage and adoption.
The 66 % revenue increase confirms robust commercial uptake of Ryoncil and underscores Mesoblast’s transition from a research‑centric organization to a commercial‑stage biotechnology company. The growth supports the company’s strategy of expanding Ryoncil indications, including adult SR‑aGvHD and inflammatory bowel disease, and provides a solid revenue foundation for future pipeline development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.